Marché mondial des médicaments antiallergiques – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des médicaments antiallergiques

Les injections contre les allergies ont suscité beaucoup d'intérêt sur le marché des médicaments antiallergiques, car elles constituent le seul traitement capable de modifier le système immunitaire et de stopper le développement de nouvelles allergies. Le marché des médicaments antiallergiques est en pleine expansion en raison de la découverte de divers types d'immunothérapie, comme « l'immunothérapie sublinguale ». Par exemple, la Food and Drug Administration américaine a approuvé en avril 2017 une pilule pour l'immunothérapie sublinguale contre les acariens de la poussière de maison pour traiter les patients adultes atteints de rhinite allergique provoquée par les acariens de la poussière de maison. Un aspect important qui stimule le marché est l'augmentation du nombre de patients souffrant de diverses allergies.

Français Data Bridge Market Research analyse que le marché des médicaments antiallergiques, qui s'élève à 27,90 milliards USD en 2022, devrait atteindre 44,47 milliards USD d'ici 2030, à un TCAC de 6,00 % au cours de la période de prévision 2023 à 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario de marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des médicaments antiallergiques  

Market Definition

Antiallergic drugs are substances that are employed to treat allergic responses. Most of these medications work by blocking the actions of released inflammatory mediators on their target cells or by preventing the production of inflammatory mediators. Allergies are a growing group of medical issues that develop when the body's immune system reacts to an outside intruder. Allergens are chemicals that cause an allergic reaction in the immune system. Watery eyes, scratchy throat, running nose, rashes, wheezing, swelling, and breathing issues are all signs of allergies.

Antiallergics Drugs Market Dynamics

Drivers

• Rise in the prevalence of allergic reactions and allergies across the globe

The increasing incidence of allergic responses and allergies worldwide is a significant element fuelling the market's expansion for antihistamine medications. Antihistamines are used to treat seasonal allergies, motion sickness, nausea, cold and cough, and anxiety. Additionally, they are employed to treat urticaria, a form of skin allergy. These are the certain factors that propel the market growth.

• An increase in funding will drive the market growth

The research of new medicines is seeing an increase in funding worldwide due to the rise in allergic reactions. For instance, Nestlé Health Science invested EUR 40 million (USD 41 million) in July 2022 to co-develop Enterome's preclinical IL-10 inducer and work together to identify other food allergy candidates. Similarly, Aimmune Therapeutics paid Xencor USD 10 million in February 2020 to in-license an investigational biological anti-allergenic medication. Xencor gave the experimental humanized monoclonal antibody AIMab7195 an exclusive worldwide license to Aimmune Therapeutics for development and sales (originally XmAb7195). The medication was initially created to treat allergic asthma. Its ability to lower blood serum IgE and decrease IgE-producing cells is based on three different mechanisms of action. All of these elements are anticipated to drive the market.

Opportunities

• The launch of new products will act as an opportunity

The new introduction of immunotherapy medicines and the increase in approval are key drivers of the market growth. The Omalizumab add-on provided effectiveness advantages and enhanced allergen immunotherapy tolerance as of December 2021. The American FDA also authorized GSK's Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps in July 2021.

Hence, during the forecast period, segment growth is anticipated to be boosted by all of the above-mentioned variables, including product introductions and the safety and efficacy of SCIT.

Restraints/Challenges

• Risks associated with antiallergics drugs

The market for antiallergic drugs will face additional challenges during the forecast period due to the high cost of treatment and pharmaceutical side effects such as dizziness, headache, vomiting, fungal infections, blood pressure, lack of appetite, and sleep issues.

This antiallergics drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiallergics drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Strides Pharma Science Limited stated that "Loratadine Softgel Capsules" had announced USFDA approval. The recently released item is a drug frequently used to treat allergies. Seasonal allergic rhinitis (SAR) and other upper respiratory tract allergies are treated with loratadine soft gel capsules.
• In 2021, Glenmark Pharmaceuticals Limited announced the "Ryaltris-AZ Nasal Spray" launch. In India, the recently released medication treats mild to severe allergic rhinitis. Being a market leader in the respiratory industry, Glenmark was the first to provide the branded generic version for treating allergic rhinitis in India at a competitive price.

Global Antiallergics Drugs Market Scope

The antiallergics drugs market is segmented on the basis of drug class, allergy type, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antihistamines
• Corticosteroids
• Epinephrine
• Allergen Immunotherapy
• Decongestants
• Others

 Allergy Type

• Skin Allergy
• Indoor
• Outdoor Allergies
• Food Allergy
• Drug Allergies
• Latex Allergy
• Insect Allergy
• Others

 Dosage

• Tablet
• Injection
• Inhalers
• Eye drops
• Others

Route of Administration

• Oral
• Intravenous
• Topical
• Others

 End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Antiallergics Drugs Market Regional Analysis/Insights

The antiallergics drugs market is analysed and market size insights and trends are provided by country, drug class, allergy type, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the antiallergics drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the antiallergics drugs market due to an increase in the number of allergy sufferers, high healthcare costs and a well-established healthcare sector in this area.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because the demand for immunotherapy treatments is increasing and healthcare infrastructure is developing quickly.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des médicaments antiallergiques

Le paysage concurrentiel du marché des médicaments antiallergiques fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des médicaments antiallergiques.

Certains des principaux acteurs opérant sur le marché des médicaments antiallergiques sont :

• Akorn, Incorporated (États-Unis)
• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Allemagne)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Bayer AG (Allemagne)
• Merck & Co., Inc. (États-Unis)
• Prestige Consumer Healthcare Inc. (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Société Bristol-Myers Squibb (États-Unis)
• Almirall, SA (Espagne)
• Zenomed Healthcare Private Limited (Inde)
• Cadila Pharmaceuticals (Inde)

SKU-66275